Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAJbwkpbyScggoskTQAcOZy_ir_X-V2i55sh7TC9Zbz3I#assertion>. }
Showing items 1 to 10 of
10
with 100 items per page.
- association type Statement assertion.
- association label "risperidone is an atypical antipsychotic agent indicated for treatment of schizophrenia in adults 1 1 alone or in combination with lithium or valproate for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults 1 2 due to janssen pharmaceuticals corporation s marketing exclusivity rights this drug product is not labeled for use in pediatric patients with schizophrenia bipolar mania or autistic disorder 1 1 1 2 1 3 adults risperidone is indicated for the acute and maintenance treatment of schizophrenia see clinical studies 14 1 adolescents due to janssen pharmaceuticals corporation s marketing exclusivity rights this drug product is not labeled for use in pediatric patients with schizophrenia pediatric use information for the treatment of pediatric patients with schizophrenia 13 to 17 years of age is approved for janssen pharmaceuticals corporation s risperidone drug products monotherapy adults and pediatrics risperidone is indicated for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults see clinical studies 14 2 due to janssen pharmaceuticals corporation s marketing exclusivity rights this drug product is not labeled for use in pediatric patients with bipolar mania pediatric use information for the treatment of pediatric patients with bipolar mania 1 to 17 years of age is approved for janssen pharmaceuticals corporation s risperidone drug products combination therapy adults the combination of risperidone with lithium or valproate is indicated for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder see clinical studies 14 3 pediatrics due to janssen pharmaceuticals corporation s marketing exclusivity rights this drug product is not labeled for use in pediatric patients with irritability associated with autistic disorder information regarding the treatment of pediatric patients with irritability associated with autistic disorder 5 to 16 years of age is approved for janssen pharmaceuticals corporation s risperidone drug products" assertion.
- association subject drugbank:DB00734 assertion.
- association predicate treats assertion.
- association object DOID_5419 assertion.
- association relation TreatmentIndication assertion.
- DOID_5419 category Disease assertion.
- drugbank:DB00734 category Drug assertion.
- association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
- association provided_by NeuroDKG assertion.